 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | UTAA06 / PersonGen Biomedicine
New P1 trial, Metastases: UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - Apr 16, 2024
P1, N=24, Recruiting, Sponsor: Peking University
- UTAA06 / PersonGen Biomedicine
A B7-H3-CAR-modified V?1 T cells showed potentanti-solid tumor potential (Section 1) - Mar 5, 2024 - Abstract #AACR2024AACR_8264;
UTAA06 exhibited extraordinary anticancer properties both in vitro and in vivo against solid tumors. Additionally, the outstanding manufacturing process of UTAA06 will facilitate the clinical application of this product.
- || UTAA06 / PersonGen Biomedicine
New P1 trial: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 16, 2023
P1, N=18, Recruiting, Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- || UTAA06 / PersonGen Biomedicine
New P1 trial: Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 10, 2023
P1, N=10, Recruiting, Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.